The aim of the present studies was to investigate the role of hepatic lactate transport via MCT1 in lipid metabolism and fibrogenesis in NASH, and to determine its potential suitability as a therapeutic target. Here, SLC16A1 is linked to metabolic dysfunction-associated steatohepatitis.